---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007002"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:03:29.268206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aligos Q3 net loss $18.6M, cash $142.3M; HBV and NASH programs advancing

## Summary
- Net loss $18.6M ($0.44 per share) vs $33.1M ($0.78) a year ago; R&D spending fell to $17.8M.
- Cash, equivalents, and investments $142.3M as of Sep 30, 2022, down from $205.8M at Dec 31, 2021.
- HBV CAM ALG-000184 initiated up-to-48-week dosing; siRNA ALG-125755 SAD in healthy volunteers ongoing.
- NASH THR-beta agonist ALG-055009 MAD data to be presented at AASLD; plans to advance to Phase 2.
- Pan-coronavirus protease inhibitor ALG-097558 entering Phase 1 enabling studies; clinical eval expected Q2 2023.

## SEC filing metadata
- accession: 0001171843-22-007002
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/0001171843-22-007002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/f8k_110222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007002
- JSON: https://secwatch.observer/filing/0001171843-22-007002.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007002.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported third quarter, September 30, 2022 results: net income Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh, EPS $(0.44).
  - Period: third quarter, September 30, 2022
  - Net income: Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh
  - EPS: $(0.44)
  - Result: reported results
  source text: Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common share of $(0.44), compared to net losses of $33.1 million or basic and diluted net loss per common share of $(0.78) for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/0001171843-22-007002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.